Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

115 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators. von Minckwitz G, et al. N Engl J Med. 2017 Jul 13;377(2):122-131. doi: 10.1056/NEJMoa1703643. Epub 2017 Jun 5. N Engl J Med. 2017. PMID: 28581356 Free PMC article. Clinical Trial.
Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity.
Bozzetti C, Musolino A, Camisa R, Bisagni G, Flora M, Bassano C, Martella E, Lagrasta C, Nizzoli R, Personeni N, Leonardi F, Cocconi G, Ardizzoni A. Bozzetti C, et al. Among authors: bisagni g. Am J Clin Oncol. 2006 Apr;29(2):171-7. doi: 10.1097/01.coc.0000204405.96572.f9. Am J Clin Oncol. 2006. PMID: 16601438
Impact of 2013 ASCO/CAP guidelines on HER2 determination of invasive breast cancer: A single institution experience using frontline dual-color FISH.
Ragazzi M, Bisagni A, Gasparini E, Kuhn E, Bassano C, Tamagnini I, Foroni M, Bortesi M, Falco G, Ferrari G, Braglia L, Savoldi L, Bologna A, Di Cicilia R, Bisagni G, Gardini G. Ragazzi M, et al. Among authors: bisagni a, bisagni g. Breast. 2017 Aug;34:65-72. doi: 10.1016/j.breast.2017.05.001. Epub 2017 May 15. Breast. 2017. PMID: 28521178
Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study.
Musolino A, Falcini F, Sikokis A, Boggiani D, Rimanti A, Pellegrino B, Silini EM, Campanini N, Barbieri E, Zamagni C, Degli Esposti R, Cortesi L, Bisagni G, Cavanna L, Frassoldati A, Sgargi P, Michiara M. Musolino A, et al. Among authors: bisagni g. Eur J Cancer. 2018 Jan;88:10-20. doi: 10.1016/j.ejca.2017.10.024. Epub 2017 Nov 23. Eur J Cancer. 2018. PMID: 29175735
Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study.
Zambetti M, Montemurro F, Morandi P, Zamagni C, Brandes AA, Bisagni G, Cagossi K, Bengala C, Gori S, Iannacone C, Stell A, Gianni L. Zambetti M, et al. Among authors: bisagni g. Eur J Cancer. 2018 Dec;105:61-70. doi: 10.1016/j.ejca.2018.09.034. Epub 2018 Nov 3. Eur J Cancer. 2018. PMID: 30396014 Clinical Trial.
A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast Cancer.
Miglietta F, Ragazzi M, Fernandes B, Griguolo G, Massa D, Girardi F, Bottosso M, Bisagni A, Zarrilli G, Porra F, Iannaccone D, Dore L, Gaudio M, Santandrea G, Fassan M, Lo Mele M, De Sanctis R, Zambelli A, Bisagni G, Guarneri V, Dieci MV. Miglietta F, et al. Among authors: bisagni a, bisagni g. Clin Cancer Res. 2023 Sep 1;29(17):3429-3437. doi: 10.1158/1078-0432.CCR-23-0480. Clin Cancer Res. 2023. PMID: 37417941 Free PMC article.
115 results